ENDRA Life Sciences (NDRA) Research & Development (2016 - 2026)

ENDRA Life Sciences (NDRA) has reported Research & Development for 11 consecutive years, with $233665.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 38.68% year-over-year to $233665.0 in Q2 2026; TTM through Jun 2026 was $2.0 million, a 16.73% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 42.01% from the prior year.
• Research & Development was $233665.0 for Q2 2026 at ENDRA Life Sciences, down from $776410.0 in the prior quarter.
• Over five years, Research & Development peaked at $1.8 million in Q2 2022 and troughed at $233665.0 in Q2 2026.
• A 5-year average of $978236.3 and a median of $785427.0 in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 55.99% in 2022 and plunged 65.17% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $1.7 million in 2022, then sank by 65.17% to $579350.0 in 2023, then rose by 10.12% to $637957.0 in 2024, then retreated by 20.35% to $508137.0 in 2025, then tumbled by 54.02% to $233665.0 in 2026.
• The last three Research & Development figures came in at $233665.0 (Q2 2026), $776410.0 (Q1 2026), and $508137.0 (Q4 2025), per Business Quant data.